https://www.globenewswire.com/fr/news-release/2025/08/05/3127167/0/en/purespring-therapeutics-receives-uk-cta-approval-for-phase-i-ii-clinical-trial-of-ps-002-in-patients-with-primary-iga-nephropathy-igan.html
Purespring Therapeutics receives UK CTA approval for Phase
First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025UK Clinical Trial Application (CTA) approval shortly follows U.S. IND...
purespring therapeuticsreceivesukctaapproval
https://www.globenewswire.com/fr/news-release/2025/08/05/3127036/0/en/purespring-therapeutics-receives-uk-cta-approval-for-phase-i-ii-clinical-trial-of-ps-002-in-patients-with-primary-iga-nephropathy-igan.html
Purespring Therapeutics receives UK CTA approval for Phase
First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025UK Clinical Trial Application (CTA) approval shortly follows U.S. IND...
purespring therapeuticsreceivesukctaapproval
https://www.biospace.com/purespring-therapeutics-presents-preclinical-data-at-the-61st-era-congress
Purespring Therapeutics presents preclinical data at the 61st ERA Congress - BioSpace
May 27, 2024 - Purespring Therapeutics is presenting preclinical data at the 61st European Renal Association Congress, showing that transgenes can be efficiently targeted to...
purespring therapeuticspresentspreclinicaldata
https://purespringtx.com/
Home - Purespring Therapeutics
Jan 8, 2026 - A precision nephrology company leading the development of targeted, first-in-class genetic therapies to preserve kidney function.
therapeutics